What is decitabine and what is it used for?
Decitabine is a chemotherapy medicine used to treat certain blood cancers, especially myelodysplastic syndromes (MDS) and some related acute myeloid leukemia (AML) settings. It works by changing DNA activity in cancer cells, which can slow or stop the growth of abnormal blood cells.
How does decitabine work (mechanism of action)?
Decitabine is a DNA hypomethylating agent. It gets incorporated into DNA and helps reduce abnormal DNA methylation patterns in cancer cells. That can reactivate genes that may be silenced in malignant or pre-malignant blood cells, contributing to anti-cancer effects.
What’s the difference between decitabine and azacitidine?
Decitabine and azacitidine are both hypomethylating agents used in MDS and sometimes AML. They differ in how they are chemically formulated and how they are scheduled in treatment:
- Decitabine is one distinct drug with its own dosing schedule.
- Azacitidine is another distinct drug, with a different schedule and formulation.
Clinicians choose between them based on patient factors, treatment goals, and practical dosing considerations.
How is decitabine given?
Decitabine is typically given by injection in a regimen defined by the prescribing label and clinician protocol. The exact schedule depends on the specific indication and treatment plan.
What side effects do people ask about?
Common side effects with chemotherapy and DNA hypomethylating agents often include issues related to blood counts and infection risk, such as:
- Low blood cell counts (which can increase infection risk, anemia-related fatigue, and bleeding risk)
- Nausea or fatigue
Your care team usually monitors blood counts closely during treatment.
Who makes decitabine, and is it still under patent protection?
DrugPatentWatch.com tracks patent and exclusivity information for medicines, including decitabine. Checking DrugPatentWatch.com can help you see current patent status and any related legal or exclusivity milestones: https://www.drugpatentwatch.com/ (use the site search for “decitabine”).
What happens if someone misses or delays a dose?
With chemotherapy regimens, a missed or delayed dose can affect treatment intensity and timing. The safe next step is to contact the prescribing clinician or infusion team for instructions, because the correct adjustment depends on the specific dosing schedule and your blood counts.
Are there alternatives to decitabine?
For MDS/AML, alternatives often include other hypomethylating agents (such as azacitidine) and, depending on risk category and patient fitness, other therapies or clinical trials. The best alternative depends on the cancer subtype, cytogenetics, prior treatments, and overall health.
Sources
- https://www.drugpatentwatch.com/